New pharmaceutical studies in Innsbruck
New pharmaceutical studies in Innsbruck
The University of Innsbruck and the Medical University of Innsbruck are opening up new career paths for students interested in science with the master’s degree in Pharmaceutical Sciences – Drug Development and Regulatory Affairs. The joint English-language course will start in the coming winter semester. Registration for the admissions process runs until May 13th.
Being part of the development and approval of next-generation drugs: The international, English-language MA program “Pharmaceutical Sciences” begins in the fall“ a new collaboration between the University of Innsbruck and the Medical University of Innsbruck. In addition to teachers from both universities, experts from the pharmaceutical industry and the regulatory authorities make a significant contribution to the attractiveness of this future-oriented course. The students acquire the basic knowledge and skills for working in pharmaceutical companies, clinical testing organizations, drug authorities and many institutions and companies in the wider healthcare sector. An intensive practical module in one of these institutions is an important element.
The range of courses includes several graduates of a bachelor’s degree in pharmacy, chemistry, biology or molecular medicine. “After completing the master’s degree, you will be able to independently and successfully plan complex projects in the context of modern drug development and to accompany them through to final market approval,” says Wolfgang Prodinger, Vice Rector for Teaching and Student Affairs at the Medical University of Innsbruck. “Students can expect a practice-oriented degree. Not only do international lectures from drug authorities and pharmaceutical industries contribute to this, but also the option of internships and master’s theses in relevant areas of drug production and supervision,” adds Bernhard Fügenschuh, Vice Rector for Teaching and Students at the University of Innsbruck.
MA Pharmaceutical Sciences – Drug Development and Regulatory Affairs
at a glance: